FDA says it explained issues early on for Corcept’s rejected Cushing’s syndrome drugnews2026-01-30T19:14:25+00:00January 30th, 2026|Endpoints News|
CHMP opposes Lilly’s Mounjaro in heart failure, backs Novo’s Kayshildnews2026-01-30T17:18:18+00:00January 30th, 2026|Endpoints News|
Ultragenyx resubmits gene therapy for rare neuro disease to FDAnews2026-01-30T16:50:40+00:00January 30th, 2026|Endpoints News|
Amgen ends partnership with Kyowa Kirin on immunology drug, despite Phase 3 winsnews2026-01-30T16:04:43+00:00January 30th, 2026|Endpoints News|
Lilly unveils $3.5B factory that will make retatrutide and other obesity drugsnews2026-01-30T16:00:33+00:00January 30th, 2026|Endpoints News|
Takeda ‘anticipated’ Medicare negotiations for top seller Entyvionews2026-01-29T19:06:42+00:00January 29th, 2026|Endpoints News|
Takeda is ‘not in favor’ of MFN, CEO-designate saysnews2026-01-29T18:01:01+00:00January 29th, 2026|Endpoints News|
White House postpones planned TrumpRx launch eventnews2026-01-29T17:57:02+00:00January 29th, 2026|Endpoints News|
Sanofi vows to stay committed to vaccines as portfolio takes a hitnews2026-01-29T16:18:36+00:00January 29th, 2026|Endpoints News|
Summit gets November PDUFA date for its PD-1xVEGF bispecificnews2026-01-29T15:07:25+00:00January 29th, 2026|Endpoints News|
